Evidence map›Paper›PMID 40083442›Full record

ArticleEClinicalMedicine2025

Bronchodilator responsiveness and future chronic airflow obstruction: a multinational longitudinal study.

Ben Knox-Brown, Fahad Algharbi, Octavia Mulhern, James Potts, Imed Harrabi, Christer Janson, Rune Nielsen, Dhiraj Agarwal, Andrei Malinovschi, Sanjay Juvekar and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Ben Knox-BrownNational Heart and Lung Institute, Imperial College London, London, UK.
Fahad AlgharbiNational Heart and Lung Institute, Imperial College London, London, UK.
Octavia MulhernNational Heart and Lung Institute, Imperial College London, London, UK.
James PottsNational Heart and Lung Institute, Imperial College London, London, UK.
Imed HarrabiIbn El Jazzar Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia.
Christer JansonDepartment of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
Rune NielsenDepartment of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
Dhiraj AgarwalVadu Rural Health Program, KEM Hospital Research Centre, Pune, India.
Andrei MalinovschiDepartment of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.
Sanjay JuvekarVadu Rural Health Program, KEM Hospital Research Centre, Pune, India.
Miriam DenguezliUniversité de Sousse, Faculté de Médecine de Sousse, LR19ES09, Sousse 4000, Tunisia.
Thorarinn GíslasonFaculty of Medicine, University of Iceland, Reykjavík, Iceland.
Rana AhmedThe Epidemiological Laboratory, Khartoum, Sudan.
Asaad NafeesDepartment of Community Health Sciences, Aga Khan University, Karachi, Pakistan.
Parvaiz A KoulSher-i-Kashmir Institute of Medical Sciences, Srinagar, J&K, India.
Daniel ObasekiObafemi Awolowo University, Ile-Ife, Osun, Nigeria.
Mahesh Padukudru AnandDepartment of Respiratory Medicine JSS Medical College, JSSAHER, India.
Li Cher LohRCSI and UCD Malaysia Campus, Penang, Malaysia.
Hermínia Brites DiasEscola Superior de Tecnologia da Saúde de Lisboa, Politécnico de Lisboa (Lisbon School of Health Technology, Polytechnic of Lisbon), Lisbon, Portugal.
Fátima RodriguesPulmonology Department, Santa Maria Local Health Unit, Lisbon, Portugal.
David ManninoUniversity of Kentucky, Lexington, KY, USA.
Mohammed ElbiazeFaculté de Médecine et de Pharmacie et de Médecine dentaire Fès, Morocco.
Karima El RhaziEpidemiology and Research in Health Sciences Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdillah University, Morocco.
Filip MejzaCentre for Evidence Based Medicine, 2nd Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland.
Graham DevereuxClinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.
Frits M E FranssenMaastricht University Medical Centre, Maastricht, the Netherlands.
Asma El SonyThe Epidemiological Laboratory, Khartoum, Sudan.
Emiel WoutersMaastricht University Medical Centre, Maastricht, the Netherlands.
Mohammed Al GhobainKing Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Kevin MortimerUniversity of Cambridge, Cambridge, UK.
Abdul RashidRCSI and UCD Malaysia Campus, Penang, Malaysia.
Rashid OsmanThe Epidemiological Laboratory, Khartoum, Sudan.
Michael StudnickaDepartment of Pulmonary Medicine, Paracelsus Medical University, Salzburg, Austria.
Joao CardosoPulmonology Department, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal.
Peter BurneyNational Heart and Lung Institute, Imperial College London, London, UK.
Andre F S AmaralNational Heart and Lung Institute, Imperial College London, London, UK.
BOLD Collaborative Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bronchodilator responsiveness testing is mainly used for diagnosing asthma. We aimed to investigate whether it is associated with progression to chronic airflow obstruction over time. Methods: The multinational Burden of Obstructive Lung Disease cohort study surveyed adults, aged 40 years and above, at baseline and followed them up after a mean of 9.1 years. Recruitment took place between January 2, 2003 and December 26, 2016. Follow-up measurements were collected between January 29, 2019 and October 24, 2021. On both occasions, study participants provided information on respiratory symptoms, health status and several environmental and lifestyle exposures. They also underwent pre- and post-bronchodilator spirometry. We defined bronchodilator responsiveness at baseline using the American Thoracic Society and European Respiratory Society (ATS/ERS) 2022 definition, and the presence of chronic airflow obstruction at follow-up as a post-bronchodilator forced expiratory volume in 1 s to forced vital capacity ratio (FEV Findings: We analysed data from 3701 adults with 56% being women. Compared to those without bronchodilator responsiveness at baseline, those with bronchodilator responsiveness had 36% increased risk of developing chronic airflow obstruction (RR: 1.36, 95%CI 1.04, 1.80). This effect was stronger in women (RR: 1.45, 95%CI 1.09, 1.91) than men (RR: 1.07, 95%CI 0.51, 2.24). Never smokers with bronchodilator responsiveness also were at greater risk of incident chronic airflow obstruction (RR: 1.48, 95%CI 1.01, 2.20). Interpretation: Bronchodilator responsiveness appears to be a risk factor for incident chronic airflow obstruction. It is important that future studies in other large population-based cohorts replicate these findings. Funding: National Heart and Lung Institute, UK Medical Research Council, and Wellcome Trust.

Indexed as

AsthmaBronchodilatorCOPDEpidemiologySpirometry

Identifiers

PMID40083442
PMCPMC11905823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.